Marchesini G, Marchignoli F, Petta S

Idioma: Español
Referencias bibliográficas: 6
Paginas: 832-834
Archivo PDF: 151.91 Kb.

RESUMEN

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30: 1356-62. 2 Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, Vianello L, et al.Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002; 137: 1-10.

2. Takyar V, Nath A, Beri A, Gharib AM, Rotman Y. How healthy are the “Healthy volunteers”? Penetrance of NAFLD in the biomedical research volunteer pool. Hepatology 2017; 66: 825-33.

3. Mofrad P, Contos MJ, Haque M, Sargeant C, Fisher RA, Luketic VA, Vianello L, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003; 37: 1286-92.

4. Fracanzani AL, Valenti L, Bugianesi E, Andreoletti M, Colli A, Vanni E, Bertelli C, et al. Risk of severe liver disease in NAFLD with normal aminotransferase levels: A role for insulin resistance and diabetes. Hepatology 2008; 48: 792-8.

5. Brill MJ, Diepstraten J, van Rongen A, van Kralingen S, van den Anker JN, Knibbe CA. Impact of obesity on drug metabolism and elimination in adults and children. Clin Pharmacokinet 2012; 51: 277-304.

6. Siddiqui MS, Sterling RK, Luketic VA, Puri P, Stravitz RT, Bouneva I, Boyett S, et al. Association between high-normal levels of alanine aminotransferase and risk factors for atherogenesis. Gastroenterology 2013; 145: 1271-9 e1-3.